| Preview | Issue Date | Title | Author(s) |
| 2009 | Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations | Muller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A. |
| 2009 | Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value | Hochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T. |
| 2013 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 | Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al. |
| 2009 | Harmonization of molecular monitoring of CML therapy in Europe | Muller, M.; Cross, N.; Erben, P.; Schenk, T.; Hanfstein, B.; Ernst, T.; Hehlmann, R.; Branford, S.; Saglio, G.; Hochhaus, A. |
| 2009 | Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase | Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A. |
| 2010 | Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) | Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J. |
| 2013 | Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia | Stein, A.; Martinelli, G.; Hughes, T.; Muller, M.; Beppu, L.; Gottardi, E.; Branford, S.; Soverini, S.; Woodman, R.; Hochhaus, A.; Kim, D.; Saglio, G.; Radich, J. |
| 2007 | Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema - An MRI study | Jorgensen, K.; Muller, M.; Nel, J.; Upton, R.; Houltz, E.; Ricksten, S. |
| 2009 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Hochhaus, A.; O'Brien, S.; Guilhot, F.; Druker, B.; Branford, S.; Foroni, L.; Goldman, J.; Muller, M.; Radich, J.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.; Larson, R. |
